DAIICHI SANKYO, INC.
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $79B
- Website
- http://daiichisankyo.us
Milademetan Plus Quizartinib Combination Study in FLT3-ITD Mutant Acute Myeloid Leukemia (AML)
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 10
- Registration Number
- NCT03552029
- Locations
- ๐บ๐ธ
Yale Cancer Center, New Haven, Connecticut, United States
๐บ๐ธRoswell Park Comprehensive Cancer Center, Buffalo, New York, United States
๐บ๐ธDuke University Cancer Center, Durham, North Carolina, United States
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
- Conditions
- Interventions
- First Posted Date
- 2018-05-18
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 524
- Registration Number
- NCT03529110
- Locations
- ๐บ๐ธ
Florida Cancer Specialists-Broadway, Fort Myers, Florida, United States
๐บ๐ธPiedmont Cancer Institute, PC, Atlanta, Georgia, United States
๐บ๐ธThe Ohio State University, Columbus, Ohio, United States
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 608
- Registration Number
- NCT03523585
- Locations
- ๐บ๐ธ
MD Anderson Cancer Center, Houston, Texas, United States
๐บ๐ธThe Methodist Hospital Research Institute, Houston, Texas, United States
๐ง๐ชAz Groeninge, Kortrijk, Belgium
Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2021-08-12
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 99
- Registration Number
- NCT03523572
- Locations
- ๐บ๐ธ
Yale University, New Haven, Connecticut, United States
๐บ๐ธIcahn School of Medicine at Mount Sinai, New York, New York, United States
๐บ๐ธTennessee Oncology - Sara Cannon Research Institute, Nashville, Tennessee, United States
DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer
- First Posted Date
- 2018-04-23
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 181
- Registration Number
- NCT03505710
- Locations
- ๐บ๐ธ
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธWashington University School of Medicine at St. Louis, Saint Louis, Missouri, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center, New York, New York, United States
Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease
- First Posted Date
- 2018-01-10
- Last Posted Date
- 2022-07-26
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 168
- Registration Number
- NCT03395639
- Locations
- ๐ญ๐ท
University Hospital Center Zagreb, Zagreb, Croatia
๐จ๐ฆCHU Sainte-Justine, Montrรฉal, Quebec, Canada
๐จ๐ฆMcMaster Children's Hospital, Hamilton, Ontario, Canada
DS-9231 in Intermediate-risk (Sub-massive) Acute Pulmonary Embolism (PE)
- First Posted Date
- 2017-10-20
- Last Posted Date
- 2018-12-24
- Lead Sponsor
- Daiichi Sankyo
- Registration Number
- NCT03316729
DS2330b Alone and With Sevelamer in Patients on Chronic Hemodialysis
- Conditions
- Interventions
- First Posted Date
- 2017-10-10
- Last Posted Date
- 2019-03-25
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 40
- Registration Number
- NCT03305471
- Locations
- ๐บ๐ธ
Orlando Clinical Research Center, Orlando, Florida, United States
๐บ๐ธDaVita Clinical Research, Minneapolis, Minnesota, United States
๐บ๐ธPrism Clinical Research, Saint Paul, Minnesota, United States
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
- Conditions
- Interventions
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2021-05-14
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 32
- Registration Number
- NCT03291288
- Locations
- ๐บ๐ธ
University of Kansas Cancer Center, Westwood, Kansas, United States
๐บ๐ธUniversity of Arizona, Tucson, Arizona, United States
๐บ๐ธHonorHealth, Scottsdale, Arizona, United States
U3-1402 in Metastatic or Unresectable Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2017-08-24
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 309
- Registration Number
- NCT03260491
- Locations
- ๐บ๐ธ
Pacific Shores Medical Group, Long Beach, California, United States
๐บ๐ธNYU Langone Health - NYU Medical Oncology Associates, New York, New York, United States
๐บ๐ธGabrail Cancer Center (GCC) - Canton Facility, Canton, Ohio, United States